IN2015MN00436A - - Google Patents
Info
- Publication number
- IN2015MN00436A IN2015MN00436A IN436MUN2015A IN2015MN00436A IN 2015MN00436 A IN2015MN00436 A IN 2015MN00436A IN 436MUN2015 A IN436MUN2015 A IN 436MUN2015A IN 2015MN00436 A IN2015MN00436 A IN 2015MN00436A
- Authority
- IN
- India
- Prior art keywords
- sequence
- protein
- contiguous nucleotides
- bont
- nucleic acid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
- A61K38/4893—Botulinum neurotoxin (3.4.24.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201219602A GB201219602D0 (en) | 2012-10-31 | 2012-10-31 | Recombinant clostridium botulinum neurotoxins |
| PCT/GB2013/052845 WO2014068317A1 (fr) | 2012-10-31 | 2013-10-31 | Neurotoxines recombinantes de clostridium botulinum |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2015MN00436A true IN2015MN00436A (fr) | 2015-09-04 |
Family
ID=47358958
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN436MUN2015 IN2015MN00436A (fr) | 2012-10-31 | 2013-10-31 |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US10030238B2 (fr) |
| EP (3) | EP3673914B1 (fr) |
| JP (2) | JP2019068823A (fr) |
| KR (2) | KR102264478B1 (fr) |
| CN (2) | CN104755098A (fr) |
| AR (2) | AR093309A1 (fr) |
| AU (3) | AU2013340610B2 (fr) |
| BR (1) | BR112015005384A2 (fr) |
| CA (1) | CA2885519A1 (fr) |
| DK (2) | DK2914282T3 (fr) |
| EA (1) | EA201590794A8 (fr) |
| ES (2) | ES2788199T3 (fr) |
| GB (1) | GB201219602D0 (fr) |
| HK (1) | HK1208359A1 (fr) |
| HU (2) | HUE036764T2 (fr) |
| IL (1) | IL237623B (fr) |
| IN (1) | IN2015MN00436A (fr) |
| MX (2) | MX367080B (fr) |
| NO (1) | NO2914282T3 (fr) |
| NZ (1) | NZ705575A (fr) |
| PL (2) | PL2914282T3 (fr) |
| PT (2) | PT3326644T (fr) |
| SG (2) | SG10201701140WA (fr) |
| TW (3) | TWI626307B (fr) |
| UA (1) | UA118837C2 (fr) |
| WO (1) | WO2014068317A1 (fr) |
| ZA (1) | ZA201501449B (fr) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201219602D0 (en) * | 2012-10-31 | 2012-12-12 | Syntaxin Ltd | Recombinant clostridium botulinum neurotoxins |
| WO2016154534A1 (fr) * | 2015-03-26 | 2016-09-29 | President And Fellows Of Harvard College | Neurotoxine botulique ingéniérisée |
| WO2017063743A1 (fr) | 2015-10-14 | 2017-04-20 | Merz Pharma Gmbh & Co. Kgaa | Améliorations apportées à la thérapie par ultrasons de tissu atteint de photovieillissement |
| AU2017227978B2 (en) | 2016-03-02 | 2022-03-10 | Merz Pharma Gmbh & Co. Kgaa | Composition comprising botulinum toxin |
| EP3263710A1 (fr) * | 2016-07-01 | 2018-01-03 | Ipsen Biopharm Limited | Production de neurotoxines clostridiales activées |
| US11117935B2 (en) | 2016-08-24 | 2021-09-14 | President And Fellows Of Harvard College | Engineered botulinum neurotoxin |
| KR102444230B1 (ko) | 2016-09-13 | 2022-09-19 | 알레간 인코포레이티드 | 안정화된 비단백질 클로스트리듐 독소 조성물 |
| WO2018233813A1 (fr) | 2017-06-20 | 2018-12-27 | Merz Pharma Gmbh & Co. Kgaa | Nouvelles toxines botuliniques recombinantes présentant une durée d'effet accrue |
| WO2019007509A1 (fr) | 2017-07-06 | 2019-01-10 | Merz Pharma Gmbh & Co. Kgaa | Nouvelles neurotoxines botuliques recombinantes présentant une durée d'effet accrue |
| WO2019145577A1 (fr) * | 2018-01-29 | 2019-08-01 | Ipsen Biopharm Limited | Neurotoxines botuliques de clivage de snare non neuronales |
| WO2019158745A1 (fr) * | 2018-02-16 | 2019-08-22 | Bontana Therapies Gmbh | Neurotoxine botulique reposant sur un acide nucléique, pour application thérapeutique |
| GB201815844D0 (en) | 2018-09-28 | 2018-11-14 | Ipsen Biopharm Ltd | Therapeutic & comestic uses of botulinum neurotoxin serotype e |
| GB202011055D0 (en) | 2020-07-17 | 2020-09-02 | Ipsen Bioinnovation Ltd | Treatment of post-operative pain |
| GB202015618D0 (en) | 2020-10-01 | 2020-11-18 | Ipsen Biopharm Ltd | Method for producing beta-trypsin |
| CN115819526A (zh) * | 2022-12-02 | 2023-03-21 | 海雅美生物技术(珠海)有限公司 | 一种重组肉毒杆菌神经毒素及其制备方法和应用 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6967088B1 (en) * | 1995-03-16 | 2005-11-22 | Allergan, Inc. | Soluble recombinant botulinum toxin proteins |
| NZ308772A (en) * | 1995-05-17 | 1999-04-29 | Du Pont | Recombinant baculovirus insecticides |
| AU759461B2 (en) | 1998-07-10 | 2003-04-17 | U.S. Medical Research Institute Of Infectious Diseases | Botulinum neurotoxin vaccine |
| EP2267008B1 (fr) | 1999-08-25 | 2014-07-02 | Allergan, Inc. | Neurotoxines recombinantes activables |
| US7374896B2 (en) | 2001-08-28 | 2008-05-20 | Allergan, Inc. | GFP-SNAP25 fluorescence release assay for botulinum neurotoxin protease activity |
| WO2006011966A1 (fr) * | 2004-06-30 | 2006-02-02 | Allergan, Inc. | Optimisation d'expression de toxine botulinum active de type e |
| US20110111483A1 (en) | 2004-06-30 | 2011-05-12 | Allergan, Inc. | Optimizing Expression of Active Botulinum Toxin Type E |
| US7514088B2 (en) * | 2005-03-15 | 2009-04-07 | Allergan, Inc. | Multivalent Clostridial toxin derivatives and methods of their use |
| GB2416122A (en) * | 2004-07-12 | 2006-01-18 | Ipsen Ltd | Botulinum neurotoxin composition |
| DE102004043009A1 (de) * | 2004-09-06 | 2006-03-23 | Toxogen Gmbh | Transportprotein zum Einbringen chemischer Verbindungen in Nervenzellen |
| DE102005002978B4 (de) | 2005-01-21 | 2013-04-25 | Merz Pharma Gmbh & Co. Kgaa | Rekombinante Expression von Proteinen in einer disulfidverbrückten, zweikettigen Form |
| DK1853623T3 (da) * | 2005-03-03 | 2013-07-15 | Allergan Inc | Dyreprodukt-frit system og fremgangsmåde til oprensning af et botulinumtoksin |
| ES2369558T3 (es) * | 2005-09-19 | 2011-12-01 | Allergan, Inc. | Toxinas clostridiales y toxinas clostridiales activables. |
| US20070218084A1 (en) * | 2005-12-30 | 2007-09-20 | Fondazione Pierfranco E Luisa Mariani- Onlus | Method for the Mapping of the Epileptogenic Focus in the Pre-Surgical Evaluation of Patients with Intractable Epilepsy |
| JP2009543558A (ja) * | 2006-07-11 | 2009-12-10 | アラーガン、インコーポレイテッド | 増強した転位置能力および増強したターゲティング活性を有する改変クロストリジウム毒素 |
| WO2009014854A1 (fr) * | 2007-07-26 | 2009-01-29 | Allergan, Inc. | Procédés d'activation de toxines clostridiales |
| CA2746425C (fr) | 2008-12-10 | 2016-05-03 | Allergan, Inc. | Compositions pharmaceutiques exemptes de proteines animales |
| GB0903006D0 (en) * | 2009-02-23 | 2009-04-08 | Syntaxin Ltd | Modified non-cytotoxic proteases |
| CN102481351B (zh) * | 2009-04-14 | 2015-05-13 | Mcw研究基金会股份有限公司 | 工程改造的肉毒杆菌神经毒素 |
| EP2512505A2 (fr) * | 2009-12-16 | 2012-10-24 | Allergan, Inc. | Toxines clostridiennes modifiées comprenant un domaine intégré de liaison au site de clivage de la protéase |
| WO2012112434A1 (fr) | 2011-02-14 | 2012-08-23 | Allergan, Inc. | Procédé permettant d'inhiber la formation de vaisseaux sanguins aberrants au moyen d'endopeptidases reciblées |
| GB201219602D0 (en) * | 2012-10-31 | 2012-12-12 | Syntaxin Ltd | Recombinant clostridium botulinum neurotoxins |
| GB201407525D0 (en) * | 2014-04-29 | 2014-06-11 | Syntaxin Ltd | Manufacture of recombinant clostridium botulinum neurotoxins |
| US11117935B2 (en) * | 2016-08-24 | 2021-09-14 | President And Fellows Of Harvard College | Engineered botulinum neurotoxin |
-
2012
- 2012-10-31 GB GB201219602A patent/GB201219602D0/en not_active Ceased
-
2013
- 2013-10-31 SG SG10201701140WA patent/SG10201701140WA/en unknown
- 2013-10-31 ES ES17201198T patent/ES2788199T3/es active Active
- 2013-10-31 HU HUE13811605A patent/HUE036764T2/hu unknown
- 2013-10-31 PL PL13811605T patent/PL2914282T3/pl unknown
- 2013-10-31 TW TW102139558A patent/TWI626307B/zh not_active IP Right Cessation
- 2013-10-31 EA EA201590794A patent/EA201590794A8/ru unknown
- 2013-10-31 CA CA2885519A patent/CA2885519A1/fr not_active Abandoned
- 2013-10-31 EP EP20153122.5A patent/EP3673914B1/fr active Active
- 2013-10-31 DK DK13811605.8T patent/DK2914282T3/en active
- 2013-10-31 WO PCT/GB2013/052845 patent/WO2014068317A1/fr active Application Filing
- 2013-10-31 AU AU2013340610A patent/AU2013340610B2/en not_active Ceased
- 2013-10-31 KR KR1020207026658A patent/KR102264478B1/ko active IP Right Grant
- 2013-10-31 BR BR112015005384A patent/BR112015005384A2/pt not_active Application Discontinuation
- 2013-10-31 SG SG11201502372SA patent/SG11201502372SA/en unknown
- 2013-10-31 AR ARP130103981A patent/AR093309A1/es active IP Right Grant
- 2013-10-31 CN CN201380047542.8A patent/CN104755098A/zh active Pending
- 2013-10-31 EP EP13811605.8A patent/EP2914282B1/fr active Active
- 2013-10-31 ES ES13811605.8T patent/ES2662402T3/es active Active
- 2013-10-31 PT PT172011983T patent/PT3326644T/pt unknown
- 2013-10-31 MX MX2015005156A patent/MX367080B/es active IP Right Grant
- 2013-10-31 PL PL17201198T patent/PL3326644T3/pl unknown
- 2013-10-31 IN IN436MUN2015 patent/IN2015MN00436A/en unknown
- 2013-10-31 TW TW107110108A patent/TWI673361B/zh not_active IP Right Cessation
- 2013-10-31 NO NO13811605A patent/NO2914282T3/no unknown
- 2013-10-31 NZ NZ705575A patent/NZ705575A/en not_active IP Right Cessation
- 2013-10-31 US US14/427,234 patent/US10030238B2/en active Active
- 2013-10-31 TW TW108125708A patent/TW202012622A/zh unknown
- 2013-10-31 HU HUE17201198A patent/HUE048802T2/hu unknown
- 2013-10-31 EP EP17201198.3A patent/EP3326644B1/fr active Active
- 2013-10-31 PT PT138116058T patent/PT2914282T/pt unknown
- 2013-10-31 CN CN201910795176.3A patent/CN110499321A/zh active Pending
- 2013-10-31 UA UAA201502159A patent/UA118837C2/uk unknown
- 2013-10-31 KR KR1020157010099A patent/KR102188539B1/ko active IP Right Grant
- 2013-10-31 DK DK17201198.3T patent/DK3326644T3/da active
-
2015
- 2015-03-03 ZA ZA2015/01449A patent/ZA201501449B/en unknown
- 2015-03-08 IL IL237623A patent/IL237623B/en active IP Right Grant
- 2015-04-23 MX MX2019009222A patent/MX2019009222A/es unknown
- 2015-09-16 HK HK15109067.2A patent/HK1208359A1/xx not_active IP Right Cessation
-
2018
- 2018-05-21 AU AU2018203556A patent/AU2018203556B2/en not_active Ceased
- 2018-12-10 JP JP2018230980A patent/JP2019068823A/ja not_active Ceased
-
2019
- 2019-12-26 AR ARP190103867A patent/AR117738A2/es unknown
-
2020
- 2020-02-05 JP JP2020017612A patent/JP2020078321A/ja active Pending
- 2020-09-30 AU AU2020244481A patent/AU2020244481A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2015MN00436A (fr) | ||
| BR112018070506A2 (pt) | produção isenta de células de ácido ribonucleico | |
| PH12014501726A1 (en) | Glyphosate resistant plants and associated methods | |
| MX2018010529A (es) | Composiciones y metodos para la produccion y administracion de acido ribonucleico. | |
| MX2013007853A (es) | Polipeptidos que tienen actividad de celobiohidrolasa y polinucleotidos que codifican los mismos. | |
| MX2014004292A (es) | Variantes de glucoamilasas y polinucleotidos que las codifican. | |
| WO2014191359A9 (fr) | Aptamères et utilisation d'aptamères dans le diagnostic et le traitement du cancer | |
| MX337919B (es) | Polipeptidos que tienen actividad de celobiohidrolasa y polinucleotidos que codifican los mismos. | |
| MY181688A (en) | Improved production of fatty acid derivatives | |
| MX337984B (es) | Variantes de alfa amilasa y polinucleotidos que codifican la misma. | |
| EA201291024A1 (ru) | Композиции эндорибонуклеаз и способы их использования | |
| MX2013003681A (es) | Ácidos nucleicos manipulados y métodos de uso de los mismos. | |
| AR092712A1 (es) | Una proteina con actividad cetosa 3-epimerasa | |
| MX366912B (es) | Producción de vacuna recombinante en e. coli mediante conjugación enzimática. | |
| MX2014004598A (es) | Variantes de alfa-amilasa y polinucleotidos que codifican las mismas. | |
| MX354704B (es) | Variantes de alfa-amilasa y polinucleotidos que codifican las mismas. | |
| NZ729980A (en) | Genes involved in noscapine production | |
| MX2015000312A (es) | Polipeptidos que tienen actividad lipasa y polinucleotidos que los codifican. | |
| BR112017020690A2 (pt) | produção livre de células de ácido ribonucleico | |
| IN2015DN03206A (fr) | ||
| MY182946A (en) | Production of organic acids by fermentation at low ph | |
| MX2014001594A (es) | Polipeptidos que tienen actividad de celulasa y polinucleotidos que los codifican. | |
| IN2015KN00073A (fr) | ||
| MX2014003403A (es) | Polipeptidos que poseen actividad proteasa y polinucleotidos que los codifican. | |
| MX2015007775A (es) | Polipeptidos que poseen actividad proteasa y polinucleotidos que los codifican. |